Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06400472 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | PHASE1 | RECRUITING | 495 | — | — | May 20, 2024 | Apr 1, 2027 | Jan 14, 2026 | 23 | United States, Australia +5 |
Number of participants with dose-limiting toxicities (DLTs)
Number of participants with DLTs
Number of participants with DLTs
Number of participants with DLTs
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4170156 (Dose-escalation, Cohort A1) | EXPERIMENTAL | Escalating doses of LY4170156 administered intravenously (IV) |
| LY4170156 (Cohort A1 Parts A and C) | EXPERIMENTAL | LY4170156 administered IV |
| LY4170156 Alone or with Itraconazole. Drug-Drug Interaction (DDI) (Cohort A1: Arm B) | EXPERIMENTAL | LY4170156 administered IV and itraconazole administered orally |
| LY4170156 (Dose-optimization, Cohort A2) | EXPERIMENTAL | Comparing 2 or more doses (evaluated during dose escalation) of LY4170156 administered IV |
| LY4170156 (Enrichment Cohort A3) | EXPERIMENTAL | Monotherapy administered IV |
| LY4170156 (Combination Cohort A4) | EXPERIMENTAL | Combination with bevacizumab administered IV |
| LY4170156 (Combination Cohort A5) | EXPERIMENTAL | Combination with carboplatin administered IV |
| LY4170156 Combination with Pembrolizumab (Dose-optimization Cohort A6) | EXPERIMENTAL | Comparing 2 or more doses (evaluated during dose escalation) of LY4170156 administered IV with pembrolizumab |
| LY4170156 (Dose-expansion, Cohort B1-B4) | EXPERIMENTAL | LY4170156 administered IV |
| Name | Type | Description |
|---|---|---|
| LY4170156 | DRUG | Intravenous |
| bevacizumab | DRUG | IV |
| carboplatin | DRUG | IV |
| Itraconazole | DRUG | oral |
| pembrolizumab | DRUG | IV |
Inclusion Criteria: * Have one of the following solid tumor cancers: * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, o...